We further investigated the effect of XAF1 tumor angiogenesis in vivo, and determined the expression of PECAM-1/CD31, a well-established endothelial cell marker [39] in tumor tissues treated with Ad5/F35-XAF1 and Ad5/F35-Ctrl (Fig. 5E). Here, XAF1 is linked to neoplasm.